Last reviewed · How we verify
Placebo (Ambrisentan-matching)
This is a placebo control matching the appearance and administration of ambrisentan, an endothelin receptor antagonist, with no active pharmacological effect.
This is a placebo control matching the appearance and administration of ambrisentan, an endothelin receptor antagonist, with no active pharmacological effect. Used for Control arm in phase 3 clinical trial of ambrisentan for pulmonary arterial hypertension.
At a glance
| Generic name | Placebo (Ambrisentan-matching) |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Pulmonary Arterial Hypertension |
| Phase | Phase 3 |
Mechanism of action
Placebo formulations are used in clinical trials to provide a blinded control arm that matches the active comparator in appearance, taste, and route of administration. This placebo is specifically designed to match ambrisentan (an endothelin receptor antagonist used in pulmonary arterial hypertension) to maintain trial blinding and allow for proper efficacy and safety assessment of the active drug.
Approved indications
- Control arm in phase 3 clinical trial of ambrisentan for pulmonary arterial hypertension
Common side effects
Key clinical trials
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (PHASE3)
- COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities (PHASE3)
- Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension (PHASE3)
- Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. (PHASE3)
- Drug Combination on Exercise Performance at High Altitude (PHASE2, PHASE3)
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis (PHASE3)
- (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF (PHASE3)
- Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: